China Medicine Corporation

China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, and dysmenorrhea; upper respiratory tract infection, acute faucitis, acute tonsillitis, acute gastroenteritis, etc.; acute and chronic hepatitis, deferment hepatitis, cholecystitis, etc.; irregular menstruation, dysmenorrhea, and amenorrhea; anemia and deficiency of vital energy; palpitation, dizziness, and fatigue; and cerebral arteriosclerosis and ischemic stroke. The company distributes its products through a sales network in China. The company was formerly known as Lounsberry Holdings III, Inc. and changed its name to China Medicine Corporation in May 2006. China Medicine Corporation was founded in 2005 and is based in Guangzhou, China.

China Medicine Corporation trades as CHME on OTC. The company is classified in Healthcare / Medical - Distribution and reports in USD.

The current profile places the business in Medical - Distribution. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $64.75M of revenue and $1.72M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

China Medicine Corporation can be compared against peers such as Health Logic Interactive Inc., CTT Pharmaceutical Holdings, Inc., DATATRAK International, Inc., Epigenomics AG, Ovation Science Inc., Procyon Corporation.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $474,241, beta of 11.80, and return on equity of +3.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CHME currently shows total debt of $9.51M and beta of 11.80. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.cmc621.com/cmc/index.php

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.